EXACT: EXtendedAnalysis for Cancer Treatment A Prospective Investigator-initiated Translational Study Evaluating Individualized Treatment Regiments Based on Respective Biomarker Analyses for Refractory Cancer Patients
试验速览
- 阶段
- 不适用
- 入组人数
- 55
- 试验地点
- 2
- 主要终点
- Use of real time biopsy to establish an individual molecular profile by using next generation sequencing
研究概览
简要总结
The purpose of this study is to prospectively validate treatment benefit of an individualized treatment concept based on molecular profiling (MP) from paraffin-embedded tumor tissue sections obtained before the start of treatment (real time biopsy).
详细描述
The treatment concept will be considered to be of clinical benefit for the individual patient if a progression-free survival (PFS) ratio (PFS on MP-based therapy / best PFS achieved by prior therapy) will be > 1.0 thus generating a patient cohort with this very property. Thereby, the null hypothesis (that ≤ 40 % of this patient population would have a PFS ratio of > 1.0) will be evaluated with each patient being his own control. For tumor types with high numbers of patients per cohort, the overall response rate (ORR) will be evaluated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Consenting patients of >19 years with advanced cancer fulfilling the criteria of having:
- •an advanced malignancy with metastatic spread refractory to conventional treatment
- •a life expectancy of >4 months,
- •the possibility to access and biopsy tumour material within 4 weeks before onset of individualized treatment,
- •a malignancy amenable to further treatment options with either cytotoxic drugs, tyrosine kinase inhibitors, monoclonal antibodies or related molecules with anti-proliferative potential to cancer cells, as assessed by the ex vivo analysis and a likelihood of treatment response according to the mathematical model (all outlined in detail above),
- •agreed to participate by their signature on an informed consent form are eligible.
排除标准
- •Presence of further treatment options, as defined by NCCN guidelines which are available in Austria representing a possible further treatment-related response by conventional therapies according to generally accepted medical evidence.
- •No fresh and viable tumor material available.
- •Current use of therapeutic warfarin.
- •Unresolved toxicity of National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (NCI CTCAE v4.0) Grade 2 or higher from previous anti-cancer therapy, except alopecia.
- •Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs.
- •A history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection.
- •A history of known glucose-6-phosphate dehydrogenase (G6PD) deficiency.
- •History of other malignancy. Subjects who have been disease-free for 5 years or those with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.
- •Uncontrolled medical conditions (i.e, diabetes mellitus, hypertension, etc), psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol)
- •unwillingness or inability to follow the procedures required in the protocol.
- •pregnant or lactating females.
- •History of alcohol or drug abuse within 6 months prior to screening.
- •No informed consent available.
结局指标
主要结局
Use of real time biopsy to establish an individual molecular profile by using next generation sequencing
时间窗: 2 years
pathological examination (includes genetic and target expression profiling, and drug sensitivity screening) to rank treatment options and the potential correlation between treatment response and progression free survival
次要结局
未报告次要终点
研究者
Gerald Prager
Univ. Prof. Dr.
Medical University of Vienna